OBJECTIVE: No data exist regarding the distribution and oxoreductase enzyme activity of 11beta hydroxysteroid dehydrogenase type 1 (11beta HSD-1) in fresh human skeletal muscle. We aimed to investigate the mRNA and protein expression of 11beta HSD-1 in fresh skeletal muscle, confirm its biological activity and determine its relationship with hexose-6-phosphate dehydrogenase (H6PDH). We also examined the muscle fibre localization of 11beta HSD-1. DESIGN: Eleven non-diabetic community volunteers underwent muscle biopsy of vastus lateralis. MEASUREMENTS: (i) 11beta HSD-1 and H6PDH mRNA expression by quantitative reverse transcription polymerase chain reaction (RT-PCR); (ii) protein localization and fibre type specificity by immunohistochemistry; and (iii) enzyme oxoreductase activity by percentage conversion of 3H cortisone to cortisol. RESULTS: 11beta HSD-1 mRNA was expressed at low levels compared to human liver. Mean DeltaCT of skeletal muscle in 11 subjects was 19.57 (range 18.40-20.79) compared to DeltaCT of 12.75 in human liver, which equates to an approximate 100-fold higher level of expression. H6PDH mRNA was also detected with a mean DeltaCT of 14.46 (range 13.13-16.60), approximately 35-fold more abundant than 11beta HSD-1 in skeletal muscle. There was a significant correlation between 11beta HSD-1 and H6PDH (r = 0.67, P = 0.03). 11beta HSD-1 immunostaining was present in all muscle specimens, with similar distribution among fast and slow twitch fibres. 11beta HSD-1 oxoreductase activity was demonstrated, with mean conversion of cortisone to cortisol of 17.7% per 200 mg of muscle per 24 h (range 7.1-29.5%). CONCLUSIONS: 11beta HSD-1 mRNA and protein is expressed in fresh human skeletal muscle along with readily demonstrable oxoreductase activity. 11beta HSD-1 localization is not muscle fibre type specific. High levels of skeletal muscle H6PDH should ensure that oxoreductase activity predominates in vivo.
OBJECTIVE: No data exist regarding the distribution and oxoreductase enzyme activity of 11beta hydroxysteroid dehydrogenase type 1 (11beta HSD-1) in fresh human skeletal muscle. We aimed to investigate the mRNA and protein expression of 11beta HSD-1 in fresh skeletal muscle, confirm its biological activity and determine its relationship with hexose-6-phosphate dehydrogenase (H6PDH). We also examined the muscle fibre localization of 11beta HSD-1. DESIGN: Eleven non-diabetic community volunteers underwent muscle biopsy of vastus lateralis. MEASUREMENTS: (i) 11beta HSD-1 and H6PDH mRNA expression by quantitative reverse transcription polymerase chain reaction (RT-PCR); (ii) protein localization and fibre type specificity by immunohistochemistry; and (iii) enzyme oxoreductase activity by percentage conversion of 3H cortisone to cortisol. RESULTS:11beta HSD-1 mRNA was expressed at low levels compared to human liver. Mean DeltaCT of skeletal muscle in 11 subjects was 19.57 (range 18.40-20.79) compared to DeltaCT of 12.75 in human liver, which equates to an approximate 100-fold higher level of expression. H6PDH mRNA was also detected with a mean DeltaCT of 14.46 (range 13.13-16.60), approximately 35-fold more abundant than 11beta HSD-1 in skeletal muscle. There was a significant correlation between 11beta HSD-1 and H6PDH (r = 0.67, P = 0.03). 11beta HSD-1 immunostaining was present in all muscle specimens, with similar distribution among fast and slow twitch fibres. 11beta HSD-1 oxoreductase activity was demonstrated, with mean conversion of cortisone to cortisol of 17.7% per 200 mg of muscle per 24 h (range 7.1-29.5%). CONCLUSIONS:11beta HSD-1 mRNA and protein is expressed in fresh human skeletal muscle along with readily demonstrable oxoreductase activity. 11beta HSD-1 localization is not muscle fibre type specific. High levels of skeletal muscle H6PDH should ensure that oxoreductase activity predominates in vivo.
Authors: Nina M Semjonous; Mark Sherlock; Pancharatnam Jeyasuria; Keith L Parker; Elizabeth A Walker; Paul M Stewart; Gareth G Lavery Journal: Endocrinology Date: 2010-11-24 Impact factor: 4.736
Authors: Katherine A Hughes; Konstantinos N Manolopoulos; Javaid Iqbal; Nicholas L Cruden; Roland H Stimson; Rebecca M Reynolds; David E Newby; Ruth Andrew; Fredrik Karpe; Brian R Walker Journal: Diabetes Date: 2012-04-17 Impact factor: 9.461
Authors: Alixe H M Kilgour; Iain J Gallagher; Alasdair M J MacLullich; Ruth Andrew; Calum D Gray; Philippa Hyde; Henning Wackerhage; Holger Husi; James A Ross; John M Starr; Karen E Chapman; Kenneth C H Fearon; Brian R Walker; Carolyn A Greig Journal: PLoS One Date: 2013-12-31 Impact factor: 3.240
Authors: Dawn E W Livingstone; Sarah L Grassick; Gillian L Currie; Brian R Walker; Ruth Andrew Journal: J Endocrinol Date: 2009-02-17 Impact factor: 4.286
Authors: Stuart A Morgan; Mark Sherlock; Laura L Gathercole; Gareth G Lavery; Carol Lenaghan; Iwona J Bujalska; David Laber; Alice Yu; Gemma Convey; Rachel Mayers; Krisztina Hegyi; Jaswinder K Sethi; Paul M Stewart; David M Smith; Jeremy W Tomlinson Journal: Diabetes Date: 2009-08-12 Impact factor: 9.461
Authors: Rowan S Hardy; Craig L Doig; Zahrah Hussain; Mary O'Leary; Stuart A Morgan; Mark J Pearson; Amy Naylor; Simon W Jones; Andrew Filer; Paul M Stewart; Christopher D Buckley; Gareth G Lavery; Mark S Cooper; Karim Raza Journal: J Pathol Date: 2016-10-18 Impact factor: 7.996